Passage Bio Corp (PASG) Total Business Assets

Graphic logo of passagebio.com (PASG)

Passage Bio, Inc. (PASG) is developing innovative treatments for rare brain pathologies in US laboratories. Serving as the primary valuation tool, this price chart illustrates total assets, which currently stand at 52.18. Exclusive patent rights ensure the company's stability, although binary test outcomes limit growth. Monetization is based on the use of AAV vectors, guaranteeing significant pricing power within the life-saving medicines segment.

Passage Bio (PASG): Cumulative Company Assets from 07/04/2022 to 10/28/2026

Analytical breakdowns for passagebio.com (PASG)

- price and consensus price forecast:
Price Rate Chart Passage Bio|PASG - Price Target Chart
- market capitalization data:
Market Capitalization Passage Bio, Inc.|PASG - Enterprise Value
- book capitalization data:
Net Asset Value per Share Passage Bio|PASG - Company Net Assets|Market Capitalization to Book Value Ratio passagebio.com|PASG - Aggregate Company Assets
- debt and liquidity data:
All Debt to Shareholders' Equity Ratio Passage Bio, Inc.|PASG - Long-Term Debt to Equity|Current Liabilities to Capital Passage Bio|PASG - Company Debts|Debts to Book Capitalization Ratio Passage Bio, Inc.
Fundamental company analysis:Passage Bio, Inc.
Finished products of Passage Bio, Inc.

Against the backdrop of aggressive R&D portfolio prioritization and cost optimization at Passage Bio, Inc. (PASG), the company's resource dynamics are becoming a critical marker of viability. This metric, reverse-calculated via ROA, combines equity and liabilities to assess the issuer's fundamental capacity, allowing asset trends by ROA to identify the balance between business expansion and the risks of excessive leverage while awaiting clinical data.

Direct competitors

BIIB (biogen.com) - Company Balance Sheet Assets|Aggregate Company Assets Neurocrine Biosciences, Inc. (NBIX)|Total Business Assets Regencell Bioscience Ltd|Axsome Therapeutics Inc - Company Total Assets|Company Assets ACADIA Corp ACAD|Cumulative Company Assets XENE (Xenon Pharmaceuticals)|vikingtherapeutics.com - Company Total Assets|Aggregate Company Assets Supernus (SUPN)|CPRX: Aggregate Asset Value|Aggregate Company Assets DNLI|HRMY (Harmony Corp) - Company Assets|Aggregate Company Assets Biohaven Ltd. BHVN|Total Asset Value of Company amylyx.com|Company Total Assets TRVI|Company Total Assets PRAX (Praxis Precision Medicines Inc)|Aggregate Company Assets AVXL|CeriBell EEG - Company Total Asset Base|Aggregate Company Assets PRTA (Prothena Corporation plc)|ALEC - Company Total Asset Base|ANNX: Company Total Assets|Omeros (OMER) - Company Total Assets|Neurogene Corp - Company Total Assets|Company Balance Sheet Assets AC Immune Inc|Voyager Therapeutics - Company Total Assets|Company Assets neumoratx.com NMRA|Cumulative Company Assets Scilex|Aggregate Asset Value Tevogen Bio Holdings Inc. TVGN|ACOG - Company Total Assets|CGTX - Aggregate Company Assets|Inhibikase Therapeutics - Company Total Assets|SAVA (cassavasciences.com) - Company Total Asset Base|Aggregate Company Assets ASRT (Assertio Holdings)|Company Assets Coya (COYA)|Vistagen Therapeutics (VTGN) - Cumulative Company Assets|Aggregate Asset Value ovidrx.com (OVID)|Company Total Assets ABOS|cervomed.com - Company Total Asset Base|Alterity Therapeutics Ltd (ATHE) - Aggregate Company Assets|CLNN - Total Business Assets|PEPG (pepgen.com) - Company Total Assets|Cumulative Company Assets Jupiter Neurosciences, Inc.|RLMD: Cumulative Company Assets|Company Total Asset Base ANVS|GRCE - Aggregate Company Assets|Total Asset Value of Company Firefly Neuroscience, Inc. (AIFF)|Company Total Assets KLTO (Klotho Neurosciences)|NeuroSense Therapeutics Ltd - Company Total Assets|Aggregate Company Assets RVPH (Reviva Pharmaceuticals)|MTVA - Company Total Asset Base|Company Total Assets NRXS (NeurAxis)|HSDT (Helius Medical Technologies) - Company Balance Sheet Assets|Aggregate Company Assets Neuphoria Therapeutics, Inc. (NEUP)|Total Business Assets Minerva|Athira Pharma, Inc. - Company Total Assets|Company Assets addextherapeutics.com ADXN|Cumulative Company Assets ALZN (Alzamend Neuro)|Cyclerion Therapeutics Inc. - Company Total Assets|Aggregate Company Assets Protagenic (PTIX)|KTTA: Aggregate Asset Value|Aggregate Company Assets CRGT|ATXI (avenuetx.com) - Company Assets|Aggregate Company Assets BrainStorm Cell Therapeutics BCLI|Total Asset Value of Company Cara Therapeutics Inc.|Company Total Assets CHRO|Company Total Assets ELYM (eliemtx.com)|Aggregate Company Assets ITCI|longboardpharma.com - Company Total Asset Base|Aggregate Company Assets MRNS (Marinus Pharmaceuticals, Inc.)|NKGN - Company Total Asset Base|NRBO: Company Total Assets|Sage Therapeutics Inc (SAGE) - Company Total Assets|Synaptogenix, Inc. - Company Total Assets|Company Balance Sheet Assets trevena.com|Vigil Neuroscience - Company Total Assets|Company Assets anewmeds.com WENA|Cumulative Company Assets Cerevel